Targeted radiosensitization with PARP1 inhibition: Optimization of therapy and identification of biomarkers of response in breast cancer

Felix Y. Feng, Corey Speers, Meilan Liu, William C. Jackson, Dominic Moon, Jacob Rinkinen, Kari Wilder-Romans, Reshma Jagsi, Lori J. Pierce

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Sustained locoregional control of breast cancer is a significant issue for certain patients. Inhibition of PARP1 is a promising strategy for radiosensitization (RS). We sought to optimize therapy with PARP1 inhibition and radiation (RT) by establishing the most effective treatment schedule, degree of PARP1-mediated RS, and identify early biomarkers predictive of efficacy in breast cancer models. Using clonogenic survival assays, we assessed intrinsic radiosensitivity and RS induced by PARP1 inhibition in breast cancer cell lines. Potential biomarkers of response were evaluated using western blotting, flow cytometry, and immunofluorescence with validation in vivo using tumor xenograft experiments. Across a panel of BC and normal breast epithelial cell lines, the PARP1 inhibitor ABT-888 preferentially radiosensitizes breast cancer (vs. normal) cells with enhancement ratios (EnhR) up to 2.3 independent of intrinsic BC subtype or BRCA mutational status. Concurrent and adjuvant therapy resulted in the highest EnhR of all schedules tested. The degree of RS did not correlate with pretreatment markers of PARP1 activity, DNA damage/repair, or cell cycle distribution. Increases in PARP1 activity 24 h after RT were associated with sensitivity after combination treatment. Findings were confirmed in breast cancer xenograft models. Our study demonstrates that PARP1 inhibition improves the therapeutic index of RT independent of BC subtype or BRCA1 mutational status and that PARP1 activity may serve as a clinically relevant biomarker of response. These studies have led to a clinical trial (TBCRC024) incorporating intratreatment biomarker analyses of PARP1 inhibitors and RT in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)81-94
Number of pages14
JournalBreast Cancer Research and Treatment
Volume147
Issue number1
DOIs
StatePublished - Aug 2014
Externally publishedYes

Fingerprint

Biomarkers
Breast Neoplasms
Radiation
Heterografts
Appointments and Schedules
Therapeutics
Cell Line
Radiation Tolerance
DNA Repair
DNA Damage
Fluorescent Antibody Technique
Cell Cycle
Flow Cytometry
Breast
Western Blotting
Epithelial Cells
Clinical Trials
Survival
Neoplasms

Keywords

  • Biomarker
  • Breast cancer
  • DNA repair
  • PARP1 inhibition
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeted radiosensitization with PARP1 inhibition : Optimization of therapy and identification of biomarkers of response in breast cancer. / Feng, Felix Y.; Speers, Corey; Liu, Meilan; Jackson, William C.; Moon, Dominic; Rinkinen, Jacob; Wilder-Romans, Kari; Jagsi, Reshma; Pierce, Lori J.

In: Breast Cancer Research and Treatment, Vol. 147, No. 1, 08.2014, p. 81-94.

Research output: Contribution to journalArticle

Feng, Felix Y. ; Speers, Corey ; Liu, Meilan ; Jackson, William C. ; Moon, Dominic ; Rinkinen, Jacob ; Wilder-Romans, Kari ; Jagsi, Reshma ; Pierce, Lori J. / Targeted radiosensitization with PARP1 inhibition : Optimization of therapy and identification of biomarkers of response in breast cancer. In: Breast Cancer Research and Treatment. 2014 ; Vol. 147, No. 1. pp. 81-94.
@article{969b01dbcb0e4783b5db70e624c55d53,
title = "Targeted radiosensitization with PARP1 inhibition: Optimization of therapy and identification of biomarkers of response in breast cancer",
abstract = "Sustained locoregional control of breast cancer is a significant issue for certain patients. Inhibition of PARP1 is a promising strategy for radiosensitization (RS). We sought to optimize therapy with PARP1 inhibition and radiation (RT) by establishing the most effective treatment schedule, degree of PARP1-mediated RS, and identify early biomarkers predictive of efficacy in breast cancer models. Using clonogenic survival assays, we assessed intrinsic radiosensitivity and RS induced by PARP1 inhibition in breast cancer cell lines. Potential biomarkers of response were evaluated using western blotting, flow cytometry, and immunofluorescence with validation in vivo using tumor xenograft experiments. Across a panel of BC and normal breast epithelial cell lines, the PARP1 inhibitor ABT-888 preferentially radiosensitizes breast cancer (vs. normal) cells with enhancement ratios (EnhR) up to 2.3 independent of intrinsic BC subtype or BRCA mutational status. Concurrent and adjuvant therapy resulted in the highest EnhR of all schedules tested. The degree of RS did not correlate with pretreatment markers of PARP1 activity, DNA damage/repair, or cell cycle distribution. Increases in PARP1 activity 24 h after RT were associated with sensitivity after combination treatment. Findings were confirmed in breast cancer xenograft models. Our study demonstrates that PARP1 inhibition improves the therapeutic index of RT independent of BC subtype or BRCA1 mutational status and that PARP1 activity may serve as a clinically relevant biomarker of response. These studies have led to a clinical trial (TBCRC024) incorporating intratreatment biomarker analyses of PARP1 inhibitors and RT in breast cancer patients.",
keywords = "Biomarker, Breast cancer, DNA repair, PARP1 inhibition, Radiation",
author = "Feng, {Felix Y.} and Corey Speers and Meilan Liu and Jackson, {William C.} and Dominic Moon and Jacob Rinkinen and Kari Wilder-Romans and Reshma Jagsi and Pierce, {Lori J.}",
year = "2014",
month = "8",
doi = "10.1007/s10549-014-3085-5",
language = "English (US)",
volume = "147",
pages = "81--94",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Targeted radiosensitization with PARP1 inhibition

T2 - Optimization of therapy and identification of biomarkers of response in breast cancer

AU - Feng, Felix Y.

AU - Speers, Corey

AU - Liu, Meilan

AU - Jackson, William C.

AU - Moon, Dominic

AU - Rinkinen, Jacob

AU - Wilder-Romans, Kari

AU - Jagsi, Reshma

AU - Pierce, Lori J.

PY - 2014/8

Y1 - 2014/8

N2 - Sustained locoregional control of breast cancer is a significant issue for certain patients. Inhibition of PARP1 is a promising strategy for radiosensitization (RS). We sought to optimize therapy with PARP1 inhibition and radiation (RT) by establishing the most effective treatment schedule, degree of PARP1-mediated RS, and identify early biomarkers predictive of efficacy in breast cancer models. Using clonogenic survival assays, we assessed intrinsic radiosensitivity and RS induced by PARP1 inhibition in breast cancer cell lines. Potential biomarkers of response were evaluated using western blotting, flow cytometry, and immunofluorescence with validation in vivo using tumor xenograft experiments. Across a panel of BC and normal breast epithelial cell lines, the PARP1 inhibitor ABT-888 preferentially radiosensitizes breast cancer (vs. normal) cells with enhancement ratios (EnhR) up to 2.3 independent of intrinsic BC subtype or BRCA mutational status. Concurrent and adjuvant therapy resulted in the highest EnhR of all schedules tested. The degree of RS did not correlate with pretreatment markers of PARP1 activity, DNA damage/repair, or cell cycle distribution. Increases in PARP1 activity 24 h after RT were associated with sensitivity after combination treatment. Findings were confirmed in breast cancer xenograft models. Our study demonstrates that PARP1 inhibition improves the therapeutic index of RT independent of BC subtype or BRCA1 mutational status and that PARP1 activity may serve as a clinically relevant biomarker of response. These studies have led to a clinical trial (TBCRC024) incorporating intratreatment biomarker analyses of PARP1 inhibitors and RT in breast cancer patients.

AB - Sustained locoregional control of breast cancer is a significant issue for certain patients. Inhibition of PARP1 is a promising strategy for radiosensitization (RS). We sought to optimize therapy with PARP1 inhibition and radiation (RT) by establishing the most effective treatment schedule, degree of PARP1-mediated RS, and identify early biomarkers predictive of efficacy in breast cancer models. Using clonogenic survival assays, we assessed intrinsic radiosensitivity and RS induced by PARP1 inhibition in breast cancer cell lines. Potential biomarkers of response were evaluated using western blotting, flow cytometry, and immunofluorescence with validation in vivo using tumor xenograft experiments. Across a panel of BC and normal breast epithelial cell lines, the PARP1 inhibitor ABT-888 preferentially radiosensitizes breast cancer (vs. normal) cells with enhancement ratios (EnhR) up to 2.3 independent of intrinsic BC subtype or BRCA mutational status. Concurrent and adjuvant therapy resulted in the highest EnhR of all schedules tested. The degree of RS did not correlate with pretreatment markers of PARP1 activity, DNA damage/repair, or cell cycle distribution. Increases in PARP1 activity 24 h after RT were associated with sensitivity after combination treatment. Findings were confirmed in breast cancer xenograft models. Our study demonstrates that PARP1 inhibition improves the therapeutic index of RT independent of BC subtype or BRCA1 mutational status and that PARP1 activity may serve as a clinically relevant biomarker of response. These studies have led to a clinical trial (TBCRC024) incorporating intratreatment biomarker analyses of PARP1 inhibitors and RT in breast cancer patients.

KW - Biomarker

KW - Breast cancer

KW - DNA repair

KW - PARP1 inhibition

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=84906046444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906046444&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3085-5

DO - 10.1007/s10549-014-3085-5

M3 - Article

C2 - 25104443

AN - SCOPUS:84906046444

VL - 147

SP - 81

EP - 94

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -